LIPELLA PHARMACEUTICALS INC. [LIPO] - Chapter 11 Bankruptcy and Asset Sale to XRAIY
On March 30, 2026, Lipella Pharmaceuticals Inc. filed for Chapter 11 bankruptcy in the Western District of Pennsylvania, and on June 4, 2026, the Bankruptcy Court approved an Asset Purchase Agreement with XRAIY for the sale of substantially all of its assets.
Why this matters
Lipella Pharmaceuticals Inc., a Delaware-incorporated company in the pharmaceutical preparations industry, focuses on developing treatments for various medical conditions. On March 30, 2026, the company filed for Chapter 11 bankruptcy in the Western District of Pennsylvania, driven by financial distress. Subsequently, on June 4, 2026, the Bankruptcy Court approved an Asset Purchase Agreement with XRAIY, allowing for the sale of substantially all of Lipella's assets under section 363 of the Bankruptcy Code. The company has cautioned that trading in its common stock during the bankruptcy proceedings is highly speculative and poses significant risks.